Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Wuxi Apptec CO Ltd (OP: WUXIF )

3.780 UNCHANGED
Last Price Updated: 1:03 PM EDT, Sep 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 3.780
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 3.780
Today's Range 3.780 - 3.780
52wk Range 3.740 - 11.60
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Week In Review: ImmuneOnco Out-Licenses Two Antibodies In $2 Billion Deal
Shanghai ImmuneOnco Biopharma out-licensed global rites (ex-China) for two of its antibodies to Instil Bio of Dallas, Texas. ImmuneOnco will receive an upfront and near-term payments of $50 million,... 
Via Talk Markets
Week In Review: Foreseen Sells ADC Rights To France's Ipsen In $1 Billion Deal
In other news, Sichuan Biokin Pharma has filed for an IPO on the Hong Kong Exchange; more on the Biosecure Act being pushed by US Speaker of the House Johnson. 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market

Performance

YTD
-64.57%
-64.57%
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
+1.07%
+1.07%
1 Year
-67.41%
-67.41%

More News

Read More
Week In Review: Sciwind, Sino Biological And Biocytogen Announce Deals
Via Talk Markets
Week In Review: AriBio Sells China Rights To Alzheimer’s Candidate In $770 Million Deal
Via Talk Markets
Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities
Via Talk Markets
Week In Review: Under Pressure From US Congress, WuXi AppTec Resigns From BIO
Via Talk Markets
Top 7 Biotech Winners Of Novo Nordisk, Eli Lilly's Outsourcing Strategy For Weight-Loss Drugs: Goldman Sachs
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.